Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Director | August 08, 2025 | August 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date August 08, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-08-08 | Direct | 22,000 |
Reported balance
After 2025-08-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-08 · Grant · Acquired 22,000 · Balance 22,000 F2: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 77,819 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 77,819 F1: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.
F2: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2025 Filed Aug 8, 2025 23:36 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075793 · tm2522995-6_4seq1.xml · derivative · entry 2 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-08-08 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 01:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (Right to Buy) · Derivative | 22,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001104659-24-043789 · tm2411149-7_4seq1.xml · derivative · entry 1 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-04-02 F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 2,631 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001104659-23-126424 · tm2332958-8_4seq1.xml · derivative · entry 2 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,631 Underlying: Common Stock · 2,631 shares Expires 2028-12-13 F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 7,519 | $1.33 | $10,000.27 |
DisclosureSEC source: 0001104659-23-126424 · tm2332958-8_4seq1.xml · nonDerivative · entry 1 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,819 F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. F2 · balance_after: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person. Read SEC document |
| July 07, 2023 Filed Jul 12, 2023 00:30 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001104659-23-080101 · tm2321021-3_4seq1.xml · derivative · entry 2 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-07 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:32 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 1,000 | $1.91 | $1,910.00 |
DisclosureSEC source: 0001104659-22-095149 · tm2224654-1_4.xml · nonDerivative · entry 1 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,300 F1 · shares: The transaction reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 1,000 shares of owned directly reported by the reporting person and reported on this Form 4. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 22:52 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 18,975 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001104659-22-090261 · tm2223355d9_4seq1.xml · derivative · entry 2 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,975 Underlying: Common Stock · 18,975 shares Expires 2032-08-10 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 23:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001104659-22-042913 · tm2211684-2_4seq1.xml · derivative · entry 2 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 17,250 shares Expires 2032-04-05 F2 · derivative.exercise_date: Reflects the grant of a stock option to purchase 17,250 shares of the Issuer's common stock, which will vest in four quarterly installments from the date of grant and becoming fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service on the applicable vesting date. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 23:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 69,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042913 · tm2211684-2_4seq1.xml · nonDerivative · entry 1 Kim Jiny · CIK 0001920967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,300 F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.